The patent includes a combination of B2m and CRP proteins that have been showed in numerous studies to be associated with PAD.
Vermillion CMO Eric Fung said this patent strengthens their IP portfolio around the development of Vasclir product under development for diagnosing PAD.
Vermillion develops diagnostic tests for cardiology, hematology, oncology,and women’s health and aids physicians to diagnose, treat and improve outcomes for patients.
